Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

Core Viewpoint - Profound Medical Corp. has successfully closed a registered direct offering of 5,142,870 common shares at a price of $7.00 per share, generating approximately $36 million in gross proceeds before fees and expenses [1][3]. Financing Details - The offering was structured as a straightforward equity investment with no warrant coverage, led by healthcare-dedicated investors alongside existing shareholders [2]. - The gross proceeds from the offering are intended for expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes [3]. Placement Agent - Konik Capital Partners, LLC acted as the exclusive placement agent for the offering [4]. Regulatory Information - The offering was made under an effective shelf registration statement on Form S-3, declared effective by the SEC on December 4, 2025 [5]. Future Plans - In addition to the registered direct offering, the company plans to complete a private placement to certain Canadian purchasers, expected to close on or before December 30, 2025, subject to necessary approvals [7]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [8]. - The company is commercializing TULSA-PRO, a technology that combines real-time MRI, AI-enhanced planning, and ultrasound for prostate disease treatment [9]. - Profound is also marketing Sonalleve, a therapeutic platform for treating uterine fibroids and other conditions, which has received various regulatory approvals [10].